Get the Stockscreener App
0.8452
4.33%
0.0351
Virax Biolabs Group Ltd stock is traded at $0.8452, with a volume of 76,992.
It is up +4.33% in the last 24 hours and up +0.62% over the past month.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
See More
Previous Close:
$0.8101
Open:
$0.8102
24h Volume:
76,992
Relative Volume:
0.79
Market Cap:
$3.67M
Revenue:
$79,300
Net Income/Loss:
$-6.92M
P/E Ratio:
-0.0445
EPS:
-18.9818
Net Cash Flow:
$-5.34M
1W Performance:
-14.53%
1M Performance:
+0.62%
6M Performance:
-49.99%
1Y Performance:
-25.20%
1-Day Range:
$0.8101
$0.8799
1-Week Range:
$0.7813
$1.03
52-Week Range:
$0.7387
$8.9999
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Name
Virax Biolabs Group Ltd
Sector
Industry
Phone
-
Address
-
Compare VRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
0.8452 | 3.52M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-25 | Initiated | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd Stock (VRAX) Latest News
Is it the right time to buy Virax Biolabs Group Limited stockEntry Signal Planner To Watch Now - jammulinksnews.com
Virax Biolabs Appoints Dr. Iain Miller as New Independent Director - TipRanks
How to build a custom watchlist for Virax Biolabs Group LimitedHigh Yield Signals with Entry Timing - Newser
Analyzing drawdowns of Virax Biolabs Group Limited with statistical toolsLow Risk Trade Timing with Analysis Metrics - Newser
Virax Biolabs Group Limited’s volatility index tracking explainedFree Risk Controlled Picks With Real Returns - Newser
Visualizing Virax Biolabs Group Limited stock with heatmapsFree Step-by-Step Trade Signal Implementation - Newser
Virax Biolabs appoints Iain Miller as independent director - Investing.com Australia
Former GE Healthcare Executive Joins Virax Board to Accelerate Diagnostic Platform Expansion - Stock Titan
Using economic indicators to assess Virax Biolabs Group Limited potentialFree Real Profit Trade Plan Suggestions - Newser
Does Virax Biolabs Group Limited stock perform well during market downturnsFree Wealth Planning Blueprint - jammulinksnews.com
Is Virax Biolabs Group Limited stock overvalued or undervaluedFree Daily Trading Room Entry - jammulinksnews.com
What are the latest earnings results for Virax Biolabs Group LimitedBuild wealth with steady, reliable stocks - jammulinksnews.com
Why is Virax Biolabs Group Limited stock attracting strong analyst attentionGet real-time alerts on top stocks - jammulinksnews.com
Technical Analysis: TGB Banquets and Hotels Limited (532845)Consistent wealth multiplication - Autocar Professional
Virax Biolabs Group Limited Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Technical Analysis: SPEL Semiconductor Limited (517166)Extraordinary performance - Autocar Professional
Is Virax Biolabs Group Limited a good long term investmentSuperior trading gains - jammulinksnews.com
What analysts say about Allient Inc. stockGame-changing returns - jammulinksnews.com
What analysts say about Virax Biolabs Group Limited stockExceptional market performance - jammulinksnews.com
AI for Trademark Infringement DetectionAlpha Stock Ideas - Newser
ICICI Prudential AMC Ltd (542631) Announces Strategic ShiftExceptional earning trajectories - jammulinksnews.com
What drives Virax Biolabs Group Limited stock priceAccelerated wealth building - Autocar Professional
Virax Biolabs receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com India
Virax Biolabs receives Nasdaq minimum bid price deficiency notice - Investing.com Australia
Virax Biolabs Gets NASDAQ Deficiency Notice: What the 180-Day Compliance Timeline Means for Investors - Stock Titan
How Virax Biolabs Group Limited stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
Why ATCH stock attracts strong analyst attentionFree Consultation - Newser
Why Virax Biolabs Group Limited stock attracts strong analyst attentionFree Stock Portfolio Optimization - Newser
What makes Virax Biolabs Group Limited stock price move sharplyHigh Probability Setups - Newser
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 0.7% – Time to Buy? - Defense World
Virax Biolabs Group Full Year 2025 Earnings: Misses Expectations - simplywall.st
Virax Biolabs Announces CFO Resignation and Transition - TipRanks
FibroBiologics names new CFO after going public last year - The Business Journals
Kaival Brands Innovations Group (NASDAQ:KAVL) Trading Down 1.2% – Time to Sell? - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 2% – Here’s What Happened - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Trading Up 6.9% – Here’s What Happened - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
FY2025 Earnings Estimate for VRAX Issued By HC Wainwright - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Yahoo Finance
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
ELISpot and FluoroSpot Assay Market Size to Hit USD 576.59 Million by 2034 - Precedence Research
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs Group Ltd Stock (VRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):